Pharmigene (ROCO:7595) EPS (Basic): NT$-1.45 (TTM As of Dec. 2025)


ROCO:7595 Pharmigene Inc ROCO:7595
56 GF Score
Price NT$7.40
GF Value NT$24.66
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pharmigene EPS (Basic)?

Pharmigene ROCO:7595 -0.54% 56 EPS (Basic) is NT$-1.45 as of Dec. 2025. GuruFocus rates ROCO:7595 with a GF Score™ of 56/100 and a GF Value™ of NT$24.66 (Possible Value Trap). The stock has 7 warning signs investors should review.

Pharmigene's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-0.63. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.45.

Pharmigene's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-0.63. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.45.

Pharmigene's EPS without NRI for the six months ended in Dec. 2025 was NT$-0.63. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.48.

During the past 3 years, the average EPS without NRI Growth Rate was -14.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -39.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Pharmigene's highest 3-Year average EPS without NRI Growth Rate was 15.70% per year. The lowest was -75.30% per year. And the median was -7.25% per year.

Pharmigene  (ROCO:7595) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pharmigene EPS (Basic) Related Terms

Pharmigene EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pharmigene's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmigene EPS (Basic) Chart

Pharmigene Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -0.54 -0.98 -1.60 -1.64 -1.45

Pharmigene Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.95 -0.96 -0.68 -0.82 -0.63
ROCO:7595
56GF Score
Pharmigene Inc ROCO:7595
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmigene EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pharmigene's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-72.995-0)/50.465
=-1.45

Pharmigene's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-31.665-0)/50.465
=-0.63

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-1.45 mean?
Pharmigene (ROCO:7595) has a EPS (Basic) of NT$-1.45 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharmigene and its competitors.
Is Pharmigene's EPS (Basic) too high?
Pharmigene's current EPS (Basic) is NT$-1.45. Overall, Pharmigene has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's EPS (Basic) compare to TMO and DHR?
Pharmigene's EPS (Basic) of NT$-1.45 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharmigene and its competitors. Pharmigene's current EPS (Basic) is NT$-1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.66, compared to a current price of NT$7.40 — trading 70% below its estimated fair value. The current EPS (Basic) is NT$-1.45. Pharmigene's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current EPS (Basic) is NT$-1.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmigene (ROCO:7595) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued. The current stock price of NT$7.40 is trading 70% below its estimated GF Value™ of NT$24.66. GuruFocus considers Pharmigene to be Possible Value Trap.

Key valuation signals for ROCO:7595:

  • EPS (Basic): NT$-1.45
  • GF Value™: NT$24.66 vs. price of NT$7.40 (70% below fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmigene Business Description

Address No. 17, Lane 171, Section 2, Jiuzong Road, 4th Floor, Neihu District, Taipei, TWN, 11494
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
56GF Score

Get the complete analysis for ROCO:7595

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$7.40
Price
NT$24.66
GF Value